Immunotherapy developments in lung, head and neck, liver and PD-1 repsonse prediction

Genomic marker predicts anti-PD-1 response in several cancers

Nivolumab extends survival for NSCLC

Nivolumab extends survival for patients with the most common lung cancer

Genomic marker predicts anti-PD-1 response in several cancers

'Liquid biopsy' may help earlier detection of lung cancer treatment resistance

Pembrolizumab found to be safe with durable responses in advanced non-small cell lung cancer

How is ganetespib regulating the response of tumour cells in lung cancer?

How will genomics be applied to patient therapy in future?

Pembrolizumab showed clinical benefit in malignant pleural mesothelioma

Pembrolizumab promising for lung cancer, clinical outcomes correlate with biomarker

New approaches and new partnership models for biomarker based clinical research